NCT05673083View on ClinicalTrials.gov

Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma

Active, not recruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Multiple Myeloma in RelapseMultiple MyelomaMultiple Myeloma, RefractoryMultiple Myeloma With Failed Remission
Trial Locations (7)

13057

Hematology-Oncology Associates of Central New York, East Syracuse

32003

Cancer Specialists of North Florida, Jacksonville

50314

Misson Cancer + Blood, Des Moines

72703

Highlands Oncology Group, Fayetteville

74146

Oklahoma Cancer Specialists and Research Institute, Tulsa

77030

Oncology Consultants, Houston

98405

Northwest Medical Specialties PLLC, Tacoma

Sponsors

Lead Sponsor

All4Cure

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

All4Cure

INDUSTRY

NCT05673083 - Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma | Biotech Hunter | Biotech Hunter